Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib modulates the signaling of cytokines that are integral to lymphocyte activation, proliferation, and function. Thus, tofacitinib therapy may result in suppression of multiple elements...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Ahadieh, Sima, French, Jonathan, Geier, Jamie, Krishnaswami, Sriram, Menon, Sujatha, Checchio, Tina, Tensfeldt, Thomas G., Hoffman, Elaine, Riese, Richard, Boy, Mary, Gómez-Reino, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704538/
https://www.ncbi.nlm.nih.gov/pubmed/26669566
http://dx.doi.org/10.1186/s13075-015-0880-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704538/
https://www.ncbi.nlm.nih.gov/pubmed/26669566
http://dx.doi.org/10.1186/s13075-015-0880-2

Ejemplares similares